stockrow
Friday 6 November 2026
Export NPCE’s income statement to Excel — free account
NeuroPace, Inc.
NPCE Healthcare Medical Devices
NeuroPace, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $100.0 million, up 25.1% from fiscal 2024.
- Revenue
- −2.95%
- EPS
- +30.8%
- Free cash flow
- −78.7%
- Total debt
- +0.68%
Quarter to June 2026, against a year earlier
12.47
0.22
−1.73%
Follow NPCE
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 5 | 5 |
+8 more TTM periods Free account |
| (122.05%) | (111.38%) | (158.74%) | (169.27%) | ||
| (18.82%) | (20.63%) | (21.44%) | (23.57%) | ||
ROIC |
(44.64%) | (53.73%) | (60.58%) | (70.97%) | |
Return on Tangible Assets |
(27.30%) | (29.91%) | (27.74%) | (31.22%) | |
Average Days of Receivables |
55.14 | 54.23 | 47.22 | 57.48 | |
Free Cash Flow per Share |
(0.34) | (0.29) | (0.35) | (0.50) | |
Free Cash Flow |
(11.61) | (9.84) | (11.34) | (16.58) | |
Capital Expenditures |
(0.37) | (0.41) | (0.33) | (0.27) | |
| Other line items | |||||
Cash ROIC |
(9.47%) | (7.72%) | (8.16%) | (12.08%) | |
Accounts Receivable Turnover |
6.94 | 6.59 | 7.75 | 7.16 | |
Accounts Payable Turnover |
4.98 | 5.05 | 9.63 | 5.91 | |
Inventory Turnover |
1.29 | 1.43 | 1.61 | 1.32 | |
Average Days of Payables |
69.01 | 76.23 | 28.47 | 84.04 | |
Days of Inventory on Hand |
297.29 | 282.05 | 238.28 | 332.06 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
28.02% | 27.77% | 27.89% | 28.37% | |
Selling, General and Administrative Expense of Revenue |
67.43% | 67.36% | 65.68% | 67.03% | |
Share Based Compensation of Revenue |
9.93% | 10.79% | 11.09% | 11.69% | |
Interest Coverage |
(2.17) | (2.46) | (2.19) | (2.43) | |
Operating CF/Net income |
0.59 | 0.44 | 0.51 | 0.68 | |
Depreciation/Fixed assets |
1.87 | 1.76 | 1.94 | 1.80 | |
Capex/Depreciation |
(0.16) | (0.18) | (0.15) | (0.14) | |
Revenue per Share |
2.90 | 2.95 | 3.06 | 2.86 | |
Operating CF per Share |
(0.33) | (0.28) | (0.34) | (0.49) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026